OSUR
OraSure Technologies, Inc. NASDAQ Listed Nov 17, 1986$3.13
Mkt Cap $225.3M
52w Low $2.08
60.3% of range
52w High $3.82
50d MA $3.05
200d MA $2.88
P/E (TTM)
-3.1x
EV/EBITDA
-3.4x
P/B
0.6x
Debt/Equity
0.0x
ROE
-20.2%
P/FCF
-3341.5x
RSI (14)
—
ATR (14)
—
Beta
0.85
50d MA
$3.05
200d MA
$2.88
Avg Volume
473.5K
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND genomics laboratory services. In addition, the company provides ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; offers Colli-Pee collection device for the volumetric collection of first void urine; and manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the academic research and commercial applications, including ancestry, disease risk management, lifestyle, and animal testing. Further, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.
220 East First Street · Bethlehem, PA 18015 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | AMC | -0.23 | -0.32 | -39.1% | 3.00 | -1.3% | +4.3% | — | — | — | — | — |
| Feb 25, 2026 | AMC | -0.17 | -0.19 | -11.8% | 2.80 | -10.4% | +10.0% | +2.3% | -6.0% | +0.7% | +1.0% | — |
| Nov 5, 2025 | AMC | -0.16 | -0.13 | +18.8% | 2.57 | -4.3% | -6.6% | +0.0% | -2.9% | +5.6% | +0.4% | — |
| Aug 5, 2025 | AMC | -0.15 | -0.19 | -26.7% | 3.12 | -10.3% | -8.3% | -3.8% | +1.1% | +0.4% | +0.4% | — |
| May 7, 2025 | AMC | -0.15 | -0.18 | -20.0% | 2.79 | -3.6% | -6.8% | -3.5% | +6.4% | -0.7% | -6.0% | — |
| Feb 25, 2025 | AMC | -0.05 | -0.06 | -20.0% | 4.00 | -17.5% | -23.5% | +2.3% | +11.2% | +2.6% | -5.6% | — |
| Nov 6, 2024 | AMC | -0.01 | -0.01 | -22.0% | 4.40 | +4.5% | -3.6% | +1.2% | -1.2% | -2.4% | -2.2% | — |
| Aug 6, 2024 | AMC | 0.04 | 0.07 | +66.7% | 4.32 | +13.7% | +0.5% | +5.8% | -8.1% | -2.6% | +1.2% | — |
| May 8, 2024 | AMC | -0.01 | 0.04 | +766.7% | 5.31 | -5.8% | -4.9% | -3.8% | +6.2% | +5.6% | -1.1% | — |
| Feb 27, 2024 | AMC | 0.09 | 0.27 | +200.0% | 7.03 | +4.1% | +10.0% | -6.9% | +1.0% | -5.2% | +1.6% | — |
| Nov 7, 2023 | AMC | 0.07 | 0.27 | +285.7% | 5.75 | +1.0% | +2.9% | +5.0% | +4.0% | +1.2% | +4.0% | — |
| Aug 3, 2023 | AMC | -0.06 | -0.07 | -16.7% | 4.49 | +7.8% | +32.3% | +7.7% | +1.4% | -3.7% | +1.0% | — |
| May 10, 2023 | AMC | 0.14 | 0.37 | +164.3% | 7.05 | +1.8% | +4.8% | -18.7% | -10.8% | -0.9% | +2.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 12 | Stephens & Co. | Maintains | Equal Weight → Equal Weight | — | $2.46 | $2.43 | -1.2% | +0.4% | -7.7% | +1.3% | -2.6% | -5.8% |
| May 19 | Evercore ISI | Maintains | In Line → In Line | — | $2.43 | $2.42 | -0.4% | +8.2% | +6.5% | -8.9% | +0.8% | -1.9% |
| May 8 | Evercore ISI | Maintains | In Line → In Line | — | $2.79 | $2.69 | -3.6% | -6.8% | -3.5% | +6.4% | -0.7% | -6.0% |
| Aug 7 | Evercore ISI | Maintains | In Line → In Line | — | $4.32 | $4.91 | +13.7% | +0.5% | +5.8% | -8.1% | -2.6% | +1.2% |
| Jul 2 | Evercore ISI | Maintains | In Line → In Line | — | $4.27 | $4.23 | -0.9% | -4.4% | -1.2% | -2.5% | +4.1% | +0.2% |
| May 13 | JP Morgan | Maintains | Neutral → Neutral | — | $4.86 | $4.83 | -0.6% | +6.2% | +5.6% | -1.1% | -3.0% | -5.9% |
| Apr 4 | Evercore ISI | Maintains | In Line → In Line | — | $6.18 | $6.20 | +0.3% | -2.8% | -0.8% | -0.7% | +0.2% | -2.4% |
| Feb 29 | JP Morgan | Maintains | Neutral → Neutral | — | $7.73 | $7.81 | +1.0% | -6.9% | +1.0% | -5.2% | +1.6% | -0.4% |
| Dec 11 | Citigroup | Maintains | Buy → Buy | — | $7.10 | $7.11 | +0.1% | -0.1% | +3.1% | +1.4% | -0.8% | +4.1% |
| Nov 8 | JP Morgan | Maintains | Neutral → Neutral | — | $5.75 | $5.81 | +1.0% | +2.9% | +5.0% | +4.0% | +1.2% | +4.0% |
| Jul 17 | Stephens & Co. | Maintains | Equal Weight → Equal Weight | — | $4.68 | $4.65 | -0.6% | -2.4% | -1.5% | +0.9% | -3.1% | +2.7% |
| May 11 | Citigroup | Maintains | Buy → Buy | — | $5.27 | $5.20 | -1.3% | -2.5% | +0.4% | +5.0% | -5.7% | +2.3% |
| Feb 24 | Citigroup | Maintains | Buy → Buy | — | $7.51 | $7.00 | -6.8% | +3.3% | +3.7% | -3.1% | -1.3% | -0.3% |
| Sep 22 | Raymond James | Downgrade | Outperform → Market Perform | — | $13.34 | $12.66 | -5.1% | -16.1% | -0.1% | -2.4% | +0.3% | -3.1% |
| Aug 4 | Raymond James | Maintains | Outperform → Outperform | — | $12.41 | $10.65 | -14.1% | -3.5% | +0.0% | -1.8% | -1.4% | -2.3% |
| Jun 28 | Raymond James | Maintains | Outperform → Outperform | — | $9.56 | $9.52 | -0.4% | +5.9% | +2.4% | -2.1% | +2.3% | -1.5% |
| May 6 | Raymond James | Maintains | Outperform → Outperform | — | $9.02 | $9.16 | +1.6% | +7.9% | +1.3% | -1.3% | -1.9% | -2.8% |
| Aug 21 | Evercore ISI | Maintains | Outperform → Outperform | — | $13.19 | $13.57 | +2.9% | +12.1% | -2.5% | +4.6% | -4.5% | -20.0% |
| Aug 10 | Citigroup | Maintains | Buy → Buy | — | $14.05 | $14.20 | +1.1% | +3.6% | -7.8% | +2.8% | -2.5% | -1.9% |
| Aug 10 | JP Morgan | Maintains | Neutral → Neutral | — | $14.05 | $14.20 | +1.1% | +3.6% | -7.8% | +2.8% | -2.5% | -1.9% |
| Aug 7 | Raymond James | Upgrade | Market Perform → Outperform | — | $13.09 | $13.77 | +5.2% | +7.3% | +3.6% | -7.8% | +2.8% | -2.5% |
| May 9 | Canaccord Genuity | Downgrade | Buy → Hold | — | $9.75 | $8.64 | -11.4% | -8.0% | +2.0% | -6.9% | +2.6% | +1.5% |
| Jul 16 | Stephens & Co. | Downgrade | Overweight → Equal Weight | — | $17.30 | $16.15 | -6.6% | -5.9% | +2.7% | -0.1% | +1.3% | +0.1% |
| Nov 2 | Jefferies | Downgrade | Buy → Hold | — | $19.02 | $14.52 | -23.7% | -27.7% | +7.7% | -2.2% | -4.4% | -3.0% |
| Aug 3 | Canaccord Genuity | Maintains | Buy → Buy | — | $17.27 | $18.73 | +8.5% | +16.7% | +2.3% | +2.9% | +1.2% | -2.4% |
| Feb 9 | Raymond James | Upgrade | Market Perform → Outperform | — | $8.85 | $10.06 | +13.7% | +18.5% | +0.2% | -0.2% | +3.5% | +2.3% |
| Dec 21 | CL King | Maintains | Buy → Buy | — | $8.88 | $9.00 | +1.4% | +1.2% | -2.7% | +0.0% | +1.3% | -0.9% |
| Sep 19 | BTIG Research | Downgrade | Buy → Neutral | — | $8.65 | $8.36 | -3.4% | -2.2% | -1.3% | +1.7% | +0.0% | -2.1% |
| Sep 19 | BTIG | Downgrade | Buy → Neutral | — | $8.65 | $8.36 | -3.4% | -2.2% | -1.3% | +1.7% | +0.0% | -2.1% |
| Aug 29 | Stephens & Co. | Upgrade | Equal Weight → Overweight | — | $7.85 | $8.24 | +5.0% | +10.3% | -0.9% | -0.1% | -0.1% | +1.9% |
| Aug 24 | Canaccord Genuity | Maintains | Buy → Buy | — | $7.00 | $7.48 | +6.9% | +10.6% | +0.3% | +1.2% | +10.3% | -0.9% |
| Aug 4 | Jefferies | Maintains | Buy → Buy | — | $6.81 | $6.95 | +2.1% | +2.5% | +4.7% | -1.0% | -0.6% | -2.1% |
| Jun 13 | Raymond James | Downgrade | Outperform → Market Perform | — | $7.78 | $7.40 | -4.9% | -12.2% | +2.3% | +0.1% | -0.7% | -0.1% |
| Nov 11 | Canaccord Genuity | Maintains | Buy → Buy | — | $6.00 | $6.04 | +0.7% | -3.3% | -2.1% | +3.3% | -0.2% | +1.7% |
| Jun 17 | Jefferies | Maintains | Buy → Buy | — | $5.65 | $5.69 | +0.7% | +1.8% | +3.5% | +1.0% | -3.0% | +0.0% |
| May 7 | JMP Securities | Downgrade | Market Outperform → Market Perform | — | $6.16 | $5.39 | -12.5% | -13.5% | +3.2% | -1.6% | -2.4% | -0.4% |
| May 7 | Jefferies | Maintains | Buy → Buy | — | $6.16 | $5.39 | -12.5% | -13.5% | +3.2% | -1.6% | -2.4% | -0.4% |
| May 6 | Canaccord Genuity | Maintains | Buy → Buy | — | $6.08 | $6.03 | -0.7% | +1.4% | -13.5% | +3.2% | -1.6% | -2.4% |
| Dec 31 | Jefferies | Maintains | Buy → Buy | — | $10.17 | $10.40 | +2.3% | -0.3% | -1.9% | +1.2% | -2.9% | +4.5% |
| Oct 16 | Canaccord Genuity | Maintains | Buy → Buy | — | $8.34 | $9.35 | +12.1% | +3.1% | -3.1% | -2.6% | +4.2% | -1.7% |
| Jun 12 | Canaccord Genuity | Maintains | Buy → Buy | — | $7.48 | $7.44 | -0.5% | +4.3% | +3.7% | +3.3% | +2.8% | +2.0% |
| Jun 12 | Jefferies | Maintains | Buy → Buy | — | $7.48 | $7.44 | -0.5% | +4.3% | +3.7% | +3.3% | +2.8% | +2.0% |
| May 8 | Raymond James | Maintains | Outperform → Outperform | — | $6.59 | $6.55 | -0.6% | -8.5% | -0.2% | +6.3% | +1.1% | -4.2% |
| Nov 7 | Stephens & Co. | Downgrade | Overweight → Equal Weight | — | $5.97 | $6.24 | +4.5% | +6.9% | +7.5% | +2.2% | +1.6% | -0.6% |
| Jul 16 | Cowen & Co. | Upgrade | Market Perform → Outperform | — | $4.62 | $4.85 | +5.0% | +6.7% | +0.6% | +4.2% | -0.4% | -2.9% |
| May 31 | Jefferies | Maintains | Buy → Buy | — | $4.47 | $4.58 | +2.5% | -2.0% | +0.5% | -1.6% | -0.2% | -0.5% |
| Mar 28 | Stephens & Co. | Maintains | Overweight → Overweight | — | $5.32 | $5.38 | +1.1% | +1.5% | -2.0% | -1.1% | -2.3% | -0.8% |
| Feb 7 | Jefferies | Maintains | Buy → Buy | — | $7.02 | $6.80 | -3.1% | -13.1% | -0.3% | -3.8% | +0.0% | -0.5% |
| Nov 8 | Jefferies | Maintains | Buy → Buy | — | $8.66 | $8.02 | -7.4% | -12.1% | -3.7% | +2.6% | -0.7% | -1.2% |
| Oct 15 | Raymond James | Maintains | Market Perform → Perform | — | $9.85 | $9.88 | +0.3% | +0.0% | -1.6% | -1.0% | -0.9% | -2.1% |
No insider trades available.
8-K · 1.01
!! High
OraSure Technologies Inc -- 8-K 1.01: Material Agreement
OraSure Technologies entered into an agreement with Altai Capital Management, potentially providing capital access or strategic partnership that could support operational funding or growth initiatives for the diagnostic testing company.
Apr 17
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
OraSure's stabilizing public health funding and near-term catalysts position it for revenue growth and margin expansion, making OSUR attractive for investors seeking profitability turnaround potential.
Mar 30
8-K · 5.02
!!! Very High
OraSure Technologies Inc -- 8-K 5.02: Executive Change
David Shulkin's resignation from OraSure Technologies' board effective March 2, 2026, removes an experienced director but signals no immediate operational concerns for the company.
Mar 5
8-K · 7.01
! Medium
OraSure Technologies Inc -- 8-K 7.01: Regulation FD Disclosure
OraSure Technologies held a February 2026 analyst webcast where management discussed full-year 2025 financial results and business developments, providing investors with updated performance guidance and strategic direction.
Feb 25
Data updated apr 26, 2026 6:04pm
· Source: massive.com